<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191892</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000684016</org_study_id>
    <secondary_id>WCTU-TOUCAN</secondary_id>
    <secondary_id>ISRCTN-68146831</secondary_id>
    <secondary_id>EUDRACT-2009-010140-33</secondary_id>
    <secondary_id>EU-21066</secondary_id>
    <secondary_id>CRUK-09/024</secondary_id>
    <secondary_id>WCTU-SPON-672-09</secondary_id>
    <secondary_id>ZENECA-WCTU-TOUCAN</secondary_id>
    <nct_id>NCT01191892</nct_id>
  </id_info>
  <brief_title>Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer</brief_title>
  <official_title>A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wales Cancer Trials Unit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wales Cancer Trials Unit</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine hydrochloride,
      work in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing. Vandetanib may stop the growth of tumor cells by blocking some
      of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet
      known whether giving carboplatin and gemcitabine hydrochloride is more effective with or
      without vandetanib as first-line therapy in treating urinary tract cancer.

      PURPOSE: This randomized phase II trial is studying giving carboplatin together with
      gemcitabine hydrochloride and to see how well it works when given with or without vandetanib
      as first-line therapy in treating patients with locally advanced or metastatic urinary tract
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the antitumor activity (as measured by progression-free survival) of
           carboplatin and gemcitabine hydrochloride with versus without vandetanib as first-line
           treatment in patients with locally advanced or metastatic urothelial cell cancer who are
           not suitable to receive cisplatin.

      Secondary

        -  To determine the safety, feasibility, and tolerability of these regimens in these
           patients.

        -  To determine the objective response rate.

        -  To determine the overall survival of patients treated with these regimens

        -  To assess the change of size of measurable lesions at 9 weeks of study therapy.

      OUTLINE: This is a multicenter study. Patients are stratified according to relevant factors.
      Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive carboplatin IV over 30 minutes on day 1, gemcitabine
           hydrochloride IV over 30 minutes on days 1 and 8, and an oral placebo once daily on days
           1-21. Treatment repeats every 3 weeks for 6 courses in the absence of disease
           progression or unacceptable toxicity.

        -  Arm II: Patient receive carboplatin and gemcitabine hydrochloride as in arm I. Patients
           also receive oral vandetanib once daily on days 1-21. Treatment repeats every 3 weeks
           for 6 courses in the absence of disease progression or unacceptable toxicity.

      Blood and urine samples may be collected for laboratory analysis at baseline and after
      completion of study.

      After completion of study treatment, patients are followed up at weeks 18, 26, 39, and 52.

      Peer Reviewed and Funded or Endorsed by Cancer Research UK.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time to event PFS, follow-up to 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability and feasibility</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of randomisation and safety profile of randomised patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate as assessed by RECIST criteria</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Proportion of patients responding to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Patients will be followed up until death by using NHS flagging service.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in size of measurable lesions 9 weeks after start of chemotherapy</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity during and after treatment as assessed by NCI CTCAE v 4.0</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <condition>Ureter Cancer</condition>
  <condition>Urethral Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Carboplatin, Gemcitabine and Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vandetanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin, Gemcitabine and vandetanib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>vandetanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>vandetanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vandetanib</intervention_name>
    <arm_group_label>vandetanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of vandetanib tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed transitional cell carcinoma (pure or mixed histology) of the
             urothelium (upper or lower urinary tract)

               -  Cancers with other pathologies are permitted provided the dominant morphology is
                  transitional cell carcinoma

          -  Radiologically measurable disease according to RECIST v 1.1 criteria

          -  Locally advanced and/or metastatic disease not amenable to curative treatment with
             surgery or radiotherapy

          -  Patient not suitable for cisplatin therapy, meeting 1 or more of the following
             criteria:

               -  More than 75 years of age

               -  ECOG performance status &gt; 2

               -  Creatinine clearance &lt; 30 mL/min

               -  Clinically significant ischemic heart disease (myocardial infarction or unstable
                  angina more than 3 but less than 12 months prior to date of randomization,
                  symptomatic angina, or NYHA class I within 3 months prior to date of
                  randomization)

               -  Prior intolerance of cisplatin

               -  Any other factor that, in the opinion of the investigator, indicates that
                  cisplatin is not suitable for the patient (e.g., unilateral hearing loss)

        PATIENT CHARACTERISTICS:

          -  See Disease Characteristics

          -  ECOG performance status 0-2

          -  Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  Creatinine clearance ≥ 30 mL/min

          -  Potassium ≥ 4.0 mmol/L OR below the CTCAE grade 1 upper limit

          -  Magnesium normal OR below the CTCAE grade 1 upper limit

          -  Serum calcium ≤ 2.9 mmol/L (If serum calcium is &lt; lower limit of normal [LLN], then
             adjusted serum calcium must be ≥ LLN)

          -  ALT/AST ≤ 2.5 times ULN

          -  Alkaline phosphatase ≤ 2.5 times ULN (&lt; 5 times ULN if judged by the investigator to
             be related to liver metastases)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier-method contraception during and for 3
             months (women) or 2 months (men) after completion of study therapy

          -  No evidence of severe or uncontrolled systemic disease or any concurrent condition
             that, in the investigator's opinion, makes it undesirable for the patient to
             participate in the trial or that would jeopardize compliance with the protocol

          -  No significant risk of cardiac complications, defined as any of the following:

               -  Clinically significant cardiovascular event (e.g., myocardial infarction,
                  superior vena cava syndrome [SVC], NYHA classification of heart disease ≥ class
                  II within 3 months prior to entry, or presence of cardiac disease that, in the
                  opinion of the investigator, significantly increases the risk of ventricular
                  arrhythmia)

               -  History of arrhythmia (multifocal premature ventricular contractions, bigeminy,
                  trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is
                  symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained
                  ventricular tachycardia

                    -  Atrial fibrillation, controlled on medication, is not exclusionary

          -  No QTc prolongation with other medications that requires discontinuation of that
             medication

          -  No congenital long QT syndrome or first-degree relative with unexplained sudden death
             under 40 years of age

          -  No QTc that is immeasurable or ≥ 480 msec on screening ECG

               -  If a patient has a QTc interval ≥ 480 msec on screening ECG, the ECG screen may
                  be repeated twice (at least 24 hours apart) and the average QTc from the three
                  screening ECGs must be &lt; 480 msec in order for the patient to be eligible for the
                  study

               -  Patients who are receiving a drug that has a risk of Torsades de Pointes are
                  excluded if QTc is ≥ 460 msec

          -  No presence of left bundle branch block

          -  No hypertension not controlled by medical therapy (systolic blood pressure &gt; 160 mm Hg
             or diastolic blood pressure &gt; 100 mm Hg)

          -  No currently active diarrhea that, in the investigator's opinion, may affect the
             ability of the patient to either absorb vandetanib or to tolerate additional diarrhea
             episodes

          -  No previous or current malignancies of other histology within the past 5 years except
             for carcinoma in situ of the cervix, adequately treated basal cell or squamous cell
             carcinoma of the skin, or prostate cancer

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 2 weeks since prior and no concurrent known potent CYP3A4 inducers (e.g.,
             barbiturates, rifampicin, rifabutin, phenytoin, carbamazepine, troglitazone,
             phenobarbital, or St. John wort) or medication that has known adverse interactions
             with vandetanib

               -  Dexamethasone (or equivalent) allowed as a pre-medication for chemotherapy

          -  At least 4 weeks since prior major surgery and complete surgical wound healing

          -  At least 30 days since prior and no other concurrent investigational agents

          -  No prior chemotherapy (unless delivered perioperatively and completed &gt; 12 months
             prior to first presentation of recurrent disease)

          -  No other concurrent anticancer drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tracie Madden</last_name>
    <phone>02920687953</phone>
    <email>toucan@cardiff.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-141-301-7095</phone>
      <email>Rob.Jones@ggc.scot.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wales Cancer Trials Unit</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF11 9LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-29-2019-6800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ayr Hospital</name>
      <address>
        <city>Ayr</city>
        <zip>KA66DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret McKernan</last_name>
      <phone>01563 825749</phone>
      <email>margaret.mckernan@aaaht.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jawaher Ansari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth General Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susannah Brock</last_name>
      <email>susannah.brock@poole.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Susannah Brock</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queens Hospital</name>
      <address>
        <city>Burton upon Trent</city>
        <zip>DE13 0RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pugazhenthi Pattu</last_name>
      <phone>01332 340131</phone>
      <email>pugazhenthi.pattu@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Pugazhenthi Pattu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velindre Hospital</name>
      <address>
        <city>City and County of Cardiff</city>
        <zip>CF142TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Lester, Jason</last_name>
      <phone>44-2920 196159</phone>
      <email>jason.lester2@wales.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jason Lester</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan McLaren</last_name>
      <email>duncan.mclaren@luht.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Duncan McLaren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calderdale Royal Infirmary</name>
      <address>
        <city>Halifax</city>
        <zip>HX30PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Gledhill</last_name>
      <phone>01484 342925</phone>
      <email>lisa.gledhill@cht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ursula Hofmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huddersfield Royal Infirmary</name>
      <address>
        <city>Huddersfield</city>
        <zip>HD3 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uschi Hofmann</last_name>
      <phone>0484 847299</phone>
      <email>uschi.hofmann@cht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Uschi Hofmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Lancaster Infirmary</name>
      <address>
        <city>Lancaster</city>
        <zip>LA1 4RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Birtle</last_name>
      <phone>01524 583219</phone>
      <email>alison.birtle@lhtr.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Alison Birtle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satinder Jagdev</last_name>
      <phone>0113 2067645</phone>
      <email>satinder.jagdev@leedsth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Satinder Jagdev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Vilarino-Varela</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Marys Hospital</name>
      <address>
        <city>London</city>
        <zip>W21NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gillian Hornzee</last_name>
      <email>Gillian.Hornzee@imperial.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Simon Stewart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W68RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Stewart</last_name>
      <email>simon.stewart@imperial.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Simon Stewart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Eliott</last_name>
      <phone>01619187214</phone>
      <email>tony.eliott@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tony Eliott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital</name>
      <address>
        <city>Northwood Middlesex</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Hoskin</last_name>
      <phone>01923 844533</phone>
      <email>peter.hoskin@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Peter Hoskin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX37LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgina Rogers</last_name>
      <email>patpandrewprotheroe@oncology.ox.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Andrew Protheroe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S102SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Evans</last_name>
      <phone>0114 226500</phone>
      <email>linda.evans@sth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Linda Evans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>S016 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Crabb</last_name>
      <email>s.j.crabb@southampton.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Simon Crabb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Surrey</city>
        <zip>GU27XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Wood</last_name>
      <phone>01483 571122</phone>
      <email>katiewood@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Katie Wood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Surrey</city>
        <zip>KT2 7QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Huddart</last_name>
      <phone>020 8661 3457</phone>
      <email>robert.huddart@icr.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Robert Huddart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2010</study_first_submitted>
  <study_first_submitted_qc>August 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2010</study_first_posted>
  <last_update_submitted>July 30, 2012</last_update_submitted>
  <last_update_submitted_qc>July 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>regional transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>anterior urethral cancer</keyword>
  <keyword>posterior urethral cancer</keyword>
  <keyword>urethral cancer associated with invasive bladder cancer</keyword>
  <keyword>ureter cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

